ETF Analysis & Opinion

The latest news in the U.S.-China trade war is that the U.S. is unlikely to extend waivers for companies to do business with Chinese handset maker Huawei.FX: The kiwi was the strongest...

The FTSE 100 has lagged its U.S. and European counterparts this year, but that doesn’t mean it doesn’t try to play catch-up. We noted that U.S. indices have respected key...

Are the valuations really too high - or is it just a case of investors getting cold feet? After seeing the unraveling of WeWork's (WEWK) carefully-laid IPO plans, other publicly-listed disruptors'...

Today ETFMG Alternative Harvest ETF (NYSE:MJ) stock hit an all-time low, leaving many investors wondering if the cannabis sector will continue to bottom out. MJ is the largest cannabis ETF worldwide...

Rite Aid (NYSE:RAD) topped earnings estimates and beat revenue expectations, sending the stock up before the market open on Thursday September 26. Which in laymans terms, basically means Rite Aid...

Foreign Markets, Fair Value and Volume: In Asia 6 out of 11 markets closed higher: Shanghai Composite +0.37%, Hang Seng -0.89%, Nikkei +0.13% In Europe 13 out of 13 markets are...

Dollar Jumped On Strong Home Sales Data US stocks resumed advancing on Wednesday after President Donald Trump said that a US-China trade deal could happen “sooner than you think.” The...

The market is absolutely hamstrung until this China trade thing is behind us. The next couple of weeks are going to be a nauseating buffet of bromides. For the short-term, I’d suggest keeping an...

In a world where Amazon (NASDAQ:AMZN) is killing its competitors, it’s tough to find another consumer company which has so consistently exceeded expectations. The sportswear giant, Nike ...

Luxury fitness company Peloton (NASDAQ:PTON) is expected to IPO on Thursday, September 26. At a price range of $26-$29 per share, the company plans to sell up to $1.1 billion of shares with an...

Acacia (NASDAQ:ACTG) has announced that the FDA has accepted the resubmitted NDA for key asset BARHEMSYS for post-operative nausea and vomiting (PONV). As expected, the FDA has categorised it as a...

InMed Pharmaceuticals Inc (TSX:IN) recently reported results for FY19 and is on track for INM-755 for epidermolysis bullosa (EB) to be in the clinic by the end of 2019. The Phase I programme will...

We’re going to push aside overdone recession fears today, so I can show you one fund you can buy for triple-digit upside. And this unsung dividend play spins off a big income stream, too: a...

Since the passage of “tax cuts,” in late 2017, the surge in corporate share buybacks has become a point of much debate. As I previously wrote, stock buybacks are once again on pace to set...